Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International, Inc. (Nasdaq: DYAI), doing business as Dyadic Applied BioSolutions, regularly issues news on its activities as a global biotechnology company producing precision-engineered, animal-free proteins and enzymes. This news page aggregates press releases and market updates that describe how Dyadic is advancing its microbial C1 and Dapibus™ expression platforms across life sciences, food and nutrition, and bio-industrial markets.
Readers can find announcements about commercial agreements and partnerships, such as collaborations with Proliant Health and Biologicals, Inzymes ApS, Fermbox Bio, BRIG BIO, and Opes Diagnostics. These items often cover milestones in recombinant serum albumin, transferrin, growth factors, non-animal dairy proteins, and industrial enzyme products like EN3ZYME™, as well as details on licensing structures, milestone payments, and revenue-sharing arrangements.
Dyadic’s news flow also includes financial results and corporate developments, including quarterly earnings releases, equity offerings, and updates on its strategic shift from a research-driven organization to a commercially focused biotechnology company. These releases highlight progress in expanding product pipelines, scaling manufacturing, and strengthening liquidity to support commercial growth.
Another recurring theme in DYAI news is technology and platform validation. Articles describe grant-funded programs with organizations such as the Bill & Melinda Gates Foundation and CEPI, peer-reviewed publications demonstrating the capabilities of the C1 platform for vaccine antigens, and the CRISPR/Cas9 license agreement with ERS Genomics that broadens Dyadic’s genetic engineering toolkit.
Investors, analysts, and industry participants can use this page to follow Dyadic’s evolving portfolio of recombinant proteins, its regional expansion efforts, and its responses to Nasdaq listing matters disclosed in SEC filings. Bookmark this section to review the company’s historical and ongoing news as it reports commercial milestones, scientific progress, and capital markets activity.
Dyadic (NASDAQ: DYAI) announced an expansion of its strategic collaboration with Fermbox Bio to broaden manufacture, commercialization, and dual-sourcing of Dyadic-developed animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets.
Key elements include Fermbox manufacturing multiple Dyadic-origin products at commercial scale, co-commercialization rights globally, inclusion of Fermbox-developed products into the joint portfolio, dual-sourcing via C1, Dapibus™ or alternative microbial systems, and a jointly managed, continuously updated product pipeline to accelerate development and shorten commercialization timelines.
Dyadic Applied BioSolutions (NASDAQ: DYAI) announced a commercial agreement with Opes Diagnostics Limited on Dec 15, 2025 to support the launch of Dyadic’s recombinant human transferrin, bovine transferrin, human FGF, and bovine FGF for serum-free cell culture media applications.
Opes will leverage existing commercial relationships to identify customers primarily in Europe, Israel, and Asia, while Dyadic retains direct-selling rights and can work with other partners. The collaboration aims to accelerate adoption across research, diagnostics, cultured meat, and biomanufacturing markets.
Dyadic (NASDAQ:DYAI) and BRIG BIO signed a Development & Commercialization Agreement on Dec 1, 2025 to jointly develop recombinant bovine alpha-lactalbumin for infant, clinical, active, and healthy-aging nutrition markets.
Under the deal, BRIG BIO will fully fund the development program and receive a global commercial license to Dyadic’s production strains in the Dapibus™ fungal expression system; Dyadic will receive milestone payments, long-term shared revenue participation, and co-marketing/sales rights. The partners target scalable, cost-effective, animal-free production to address a market projected from ~USD 760M (2025) to >USD 1.6B (2035).
Dyadic (NASDAQ: DYAI) reported Q3 2025 results and strategic progress on Nov 12, 2025, highlighting a commercial pivot and rebrand to Dyadic Applied BioSolutions. Key updates include a non-exclusive CRISPR/Cas9 license with ERS Genomics, first purchase orders in cell culture media and reagent segments, peer-reviewed validation of the C1 platform for SARS-CoV-2 spike production, and multiple program milestones across life sciences, nutrition, and bioindustrial markets.
Financially, Dyadic held $10.4M cash and equivalents as of Sept 30, 2025, completed an equity offering that raised net proceeds of $4.9M, reported Q3 revenue of $1.165M (down from $1.958M YoY), and a net loss of $1.976M (or $(0.06) per share).
Dyadic Applied BioSolutions (NASDAQ:DYAI) announced a commercial CRISPR/Cas9 license from ERS Genomics on Nov 10, 2025, granting access to ERS’ global patent portfolio to support genetic engineering across Dyadic’s C1 and Dapibus bioproduction platforms. The license is intended to accelerate strain engineering, pathway optimization, and integration of CRISPR gene editing into Dyadic’s internal pipeline and partner projects across life sciences, food & nutrition, and bio-industrial sectors.
ERS Genomics holds a portfolio of 100+ patents and reports 150+ licenses worldwide; financial terms of this agreement were not disclosed.
Dyadic Applied BioSolutions (Nasdaq: DYAI) announced it will report its financial results and host a corporate update conference call on Wednesday, November 12, 2025 at 5:00 p.m. ET.
The company notes a dial-in (Toll Free +1-877-407-0784; International +1-201-689-8560) and Conference ID 13751389, plus a live webcast and a replay available within 24 hours on the investor relations website. Investors may submit Q&A questions in advance via jlavalley@dyadic.com.
Dyadic Applied BioSolutions (NASDAQ: DYAI) reported commercial and product milestones in Q3 2025, including milestone payments and progress across life sciences and food & nutrition programs.
Key discrete items: a $500,000 productivity milestone for recombinant human albumin with payment expected in Q4 2025, and a $250,000 milestone received from the Inzymes partnership after Q3 2025 productivity improvements. Proliant has begun sampling albumin with a commercial launch targeted in late 2025–early 2026. Dyadic also reported sampling/production starts for transferrin, research-grade DNase I meeting activity and purity benchmarks, and a signed term sheet for non-animal human alpha-lactalbumin for infant nutrition. Several enzyme candidates are advancing with scale-up on track for late 2025.
Dyadic International (NASDAQ:DYAI), a biotechnology company specializing in precision engineered functional input proteins, has announced its participation in three upcoming conferences in September 2025.
The company's President & COO Joe Hazelton will present at the H.C. Wainwright Global Investment Conference (Sept 8-10), BioProcess International BPI East (Sept 15-18), and the Sidoti Small Cap Investor Event (Sept 17-18). Interested parties can schedule meetings with management by contacting jlavalley@dyadic.com.
Dyadic International (NASDAQ: DYAI) reported Q2 2025 financial results and strategic developments, marking its transformation from R&D to commercial operations. The company has rebranded as Dyadic Applied BioSolutions and completed a $5.3 million equity offering to strengthen its position.
Q2 financial highlights include revenue of $967,000 (up from $386,000 YoY), with a reduced net loss of $1.794 million ($0.06 per share). Cash position stands at $7.3 million as of June 30, 2025, plus $5.3 million from the August offering.
Key developments include advancing commercial launches of DNase I and recombinant albumin with Proliant, receiving $1.0 million in milestone payments, and progress in multiple protein programs across life sciences, nutrition, and bio-industrial markets. The company also secured grants from the Gates Foundation and CEPI for vaccine development.
Dyadic International (Nasdaq: DYAI), a global biotechnology company specializing in precision engineered functional input proteins, has scheduled its second quarter 2025 financial results announcement and corporate update conference call for Wednesday, August 13, 2025, at 5:00 p.m. Eastern Time.
The company will host a conference call accessible via toll-free and international dial-in numbers, with a webcast available through their investor relations website. Participants can submit questions for the Q&A session by emailing them in advance.
FAQ
What is the current stock price of Dyadic Intl Del (DYAI)?
What is the market cap of Dyadic Intl Del (DYAI)?
